QU

QuantaMatrix Incorporated

IVD specialist in rapid antimicrobial susceptibility testing for critical infections like sepsis.

317690 | KO

Overview

Corporate Details

ISIN(s):
KR7317690006
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131 B동 16층(가산동, 비와이씨하이시티), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

QuantaMatrix Inc. is an in-vitro diagnostics (IVD) company specializing in innovative solutions for clinical microbiology. The company develops and manufactures medical devices that utilize proprietary technologies, including time-lapse microscopic imaging and microfluidics, to accelerate pathogen identification and antimicrobial susceptibility testing (AST). Its primary focus is on critical infections such as sepsis, with its dRAST™ (direct Rapid Antimicrobial Susceptibility Test) system designed to provide results significantly faster than conventional methods. By enabling quicker and more accurate diagnoses, QuantaMatrix aims to improve patient outcomes, facilitate timely antibiotic treatment, and help combat antimicrobial resistance. The company's platforms also serve molecular and immunoassay applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 881.8 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 5.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.3 KB
2025-07-17 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-07-15 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]수시공시의무관련사항(공정공시) (유상증자 계획)
Korean 11.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 960.9 KB
2025-03-28 00:00
AGM Information
정기주주총회결과
Korean 24.1 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 167.0 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-12 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.8 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.9 KB

Automate Your Workflow. Get a real-time feed of all QuantaMatrix Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QuantaMatrix Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QuantaMatrix Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America
ALNY
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufactures critical reagents for biopharma, scaling from research to GMP manufacturing.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Altimmune, Inc. Logo
Developing novel peptide therapeutics for obesity, liver, and cardiometabolic diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN

Talk to a Data Expert

Have a question? We'll get back to you promptly.